Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 313
Filtrar
1.
Arterioscler Thromb Vasc Biol ; 41(6): 1915-1927, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33853347
2.
Transplant Proc ; 45(2): 639-42, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23498803

RESUMO

UNLABELLED: The aim of this study was to explore underlying mechanisms of transplant arteriosclerosis (TA) based on intimal thickening that involve activation of vascular smooth muscle cells (VSMCs) and angiogenesis. We also examined the effects of adenovirus-mediated anti-sense extracellular signal-regulated kinase 2 (ERK2) (Adanti-ERK2) gene therapy on TA. METHODS: We employed a rat aorta transplantation model (Brown-Norway → Lewis). The animals were divided into: (1) an isograft group (n = 6), (2) an empty control group (n = 6), (3) the Ad-LacZ group (n = 6), and (4) the adanti-ERK2 group (n = 6). At 60 days after transplantation, we documented the ratio of intima/(intima + media) the isografts pathologically. Staining for α-actin and platelet-derived growth factor (PDGF)-BB was performed to analyze the migration and secretion of VSMCs. We evaluated angiogenesis and COX-2 staining. RESULT: Isografts showed normal histology; allografts from the empty control group and the Ad-LacZ group displayed typical TA lesions, while the pathology was significantly improved among the adanti-ERK2 group. The ratios of intima/(intima + media) were 7.6 ± 2.1%, 81.4% ± 6.7%, 85.9% ± 9.4%, and 15.9% ± 4.1% among the isograft group, the empty control, the Ad-LacZ, and the adanti-ERK2 groups respectively. The α-actin+ cells in the intima per field (×400) were 2.1 ± 1.1, 71.3 ± 9.2, 76.4 ± 11.3, and 34.8 ± 5.3, PDGF-BB+ cells, 0.9 ± 0.5, 28.4 ± 3.4, 29.1 ± 3.2, and 8.6 ± 1.7; COX-2+ cells in new capillaries were none, 36.3 ± 8.3, 40.9 ± 9.2, and 10.4 ± 3.9 respectively (P < .05). CONCLUSION: Intimal thickening a key feature of TA, involves activation of VSMC (proliferation, migration and secretion), and the accompanying angiogenesis. Adanti-ERK2 gene therapy modulates the mechanisms, protecting allografts against TA.


Assuntos
Adenoviridae/genética , Aorta Abdominal/transplante , Arteriosclerose/prevenção & controle , DNA Antissenso/metabolismo , Terapia Genética/métodos , Vetores Genéticos , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Músculo Liso Vascular/transplante , Neovascularização Patológica , Transdução Genética , Animais , Aorta Abdominal/enzimologia , Aorta Abdominal/patologia , Arteriosclerose/enzimologia , Arteriosclerose/genética , Arteriosclerose/patologia , Becaplermina , Movimento Celular , Proliferação de Células , Ciclo-Oxigenase 2/metabolismo , DNA Antissenso/genética , Proteína Quinase 1 Ativada por Mitógeno/genética , Músculo Liso Vascular/enzimologia , Músculo Liso Vascular/patologia , Miócitos de Músculo Liso/enzimologia , Miócitos de Músculo Liso/patologia , Miócitos de Músculo Liso/transplante , Neointima , Proteínas Proto-Oncogênicas c-sis/metabolismo , Ratos , Ratos Endogâmicos BN , Ratos Endogâmicos Lew
3.
Nucleus ; 1(3): 245-8, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21327070

RESUMO

The SNF2 family of ATPases acts in the context of chromatin to regulate transcription, replication, repair and recombination. Defects in SNF2 genes cause many human diseases. For example, mutations in SMARCAL1 (also named HARP) cause Schimke immuno-osseous dysplasia (SIOD); a multi-system disorder characterized by growth defects, immune deficiencies, renal failure and other complex phenotypes. Several groups including ours recently identified SMARCAL1 as a replication stress response protein. Importantly, SMARCAL1 localizes to stalled replication forks and this localization of SMARCAL1 activity prevents DNA damage accumulation during DNA replication. We determined that SIOD-related SMARCAL1 mutants could not prevent replication-associated DNA damage in cells in which endogenous SMARCAL1 was silenced, establishing the first link between SIOD and a defect in a specific biological activity. Here, we also report that cells from patients with SIOD exhibit elevated levels of DNA damage that can be rescued by re-introduction of wild-type SMARCAL1. Our data suggest that loss of SMARCAL1 function in patients may cause DNA replication-associated genome instability that contributes to the pleiotropic phenotypes of SIOD.


Assuntos
Arteriosclerose/enzimologia , Arteriosclerose/genética , Dano ao DNA , DNA Helicases/metabolismo , Replicação do DNA/genética , Síndromes de Imunodeficiência/enzimologia , Síndromes de Imunodeficiência/genética , Síndrome Nefrótica/enzimologia , Síndrome Nefrótica/genética , Osteocondrodisplasias/enzimologia , Osteocondrodisplasias/genética , Embolia Pulmonar/enzimologia , Embolia Pulmonar/genética , DNA Helicases/deficiência , DNA Helicases/genética , Inativação Gênica , Humanos , Doenças da Imunodeficiência Primária
4.
Vascular ; 17 Suppl 1: S40-4, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19426608

RESUMO

Arterial calcification is now understood to be an actively regulated process with promoters and inhibitors similar to those seen remodeling bone. It occurs in two distinct forms involving either the atherosclerotic intimal or the media. The amount of calcification found in the tibial arteries of the lower extremity is a better predictor of amputation than atherosclerosis risk factors and the ankle brachial index. We and others have recently demonstrated that matrix metalloproteinases (MMPs) play a critical role in the development of experimental arterial calcification in rodent models. The mechanisms by which MMPs may regulate arterial calcification, however, are not completely understood. While MMPs have traditionally been thought to function primarily in the degradation of extracellular matrix molecules, recent data suggest that MMPs may also function as important regulators of matrix biology, inflammation, and osteogenesis. In this review, we will examine recent data on the potential mechanisms by which MMPs may function in the control of arterial calcification.


Assuntos
Artérias/enzimologia , Arteriosclerose/enzimologia , Calcinose/enzimologia , Metaloproteinases da Matriz/fisiologia , Animais , Artérias/imunologia , Artérias/patologia , Arteriosclerose/imunologia , Arteriosclerose/patologia , Calcinose/imunologia , Calcinose/patologia , Matriz Extracelular/enzimologia , Matriz Extracelular/imunologia , Matriz Extracelular/patologia , Humanos , Inflamação , Camundongos , Modelos Animais , Ratos , Túnica Íntima/enzimologia , Túnica Íntima/imunologia , Túnica Íntima/patologia
5.
Postepy Biochem ; 55(4): 373-84, 2009.
Artigo em Polonês | MEDLINE | ID: mdl-20201350

RESUMO

Aminoacyl-tRNA synthetases (aaRS) are essential proteins of all living organisms. It is known that they ensure the fidelity of transfer of genetic information from the DNA into the protein. Not far away it occurred that their role is not confined to catalyze the attachment of amino acids to transfer RNAs and thereby establish the rules of genetic code by virtue of matching the nucleotide triplet of anticodon with cognate amino acid. aaRSs are also engaged in the other crucial cellular processes. So the disturbance of function of any of them often causes serious disorders. Therefore this proteins could be an attractive target of drugs, not only against the mentioned illnesses but also against bacterial, fungal and parasitic infections. Constant progress on this field makes aaRSs still an interesting object of researches.


Assuntos
Aminoacil-tRNA Sintetases/antagonistas & inibidores , Aminoacil-tRNA Sintetases/metabolismo , Aminoacil-tRNA Sintetases/genética , Arteriosclerose/tratamento farmacológico , Arteriosclerose/enzimologia , Doenças Autoimunes/enzimologia , Humanos , Infecções/tratamento farmacológico , Infecções/enzimologia , Mutação , Neoplasias/tratamento farmacológico , Neoplasias/enzimologia , Doenças do Sistema Nervoso/tratamento farmacológico , Doenças do Sistema Nervoso/enzimologia
6.
J Am Coll Cardiol ; 52(10): 843-50, 2008 Sep 02.
Artigo em Inglês | MEDLINE | ID: mdl-18755348

RESUMO

OBJECTIVES: The aim of this study was to determine whether oxidative stress is increased in calcified, stenotic aortic valves and to examine mechanisms that might contribute to increased oxidative stress. BACKGROUND: Oxidative stress is increased in atherosclerotic lesions and might play an important role in plaque progression and calcification. The role of oxidative stress in valve disease is not clear. METHODS: Superoxide (dihydroethidium fluorescence and lucigenin-enhanced chemiluminescence), hydrogen peroxide H2O2 (dichlorofluorescein fluorescence), and expression and activity of pro- and anti-oxidant enzymes were measured in normal valves from hearts not suitable for transplantation and stenotic aortic valves that were removed during surgical replacement of the valve. RESULTS: In normal valves, superoxide levels were relatively low and distributed homogeneously throughout the valve. In stenotic valves, superoxide levels were increased 2-fold near the calcified regions of the valve (p < 0.05); noncalcified regions did not differ significantly from normal valves. Hydrogen peroxide levels were also markedly elevated in calcified regions of stenotic valves. Nicotinamide adenine dinucleotide phosphate oxidase activity was not increased in calcified regions of stenotic valves. Superoxide levels in stenotic valves were significantly reduced by inhibition of nitric oxide synthases (NOS), which suggests uncoupling of the enzyme. Antioxidant mechanisms were reduced in calcified regions of the aortic valve, because total superoxide dismutase (SOD) activity and expression of all 3 SOD isoforms was significantly decreased. Catalase expression also was reduced in pericalcific regions. CONCLUSIONS: This study provides the first evidence that oxidative stress is increased in calcified regions of stenotic aortic valves from humans. Increased oxidative stress is due at least in part to reduction in expression and activity of antioxidant enzymes and perhaps to uncoupled NOS activity. Thus, mechanisms of oxidative stress differ greatly between stenotic aortic valves and atherosclerotic arteries.


Assuntos
Antioxidantes/metabolismo , Estenose da Valva Aórtica/fisiopatologia , Arteriosclerose/fisiopatologia , Calcinose/fisiopatologia , Diferenciação Celular , Estresse Oxidativo , Estenose da Valva Aórtica/enzimologia , Arteriosclerose/enzimologia , Calcinose/enzimologia , Progressão da Doença , Humanos , Peróxido de Hidrogênio/metabolismo , Inflamação/fisiopatologia , NADP/metabolismo , Óxido Nítrico Sintase/metabolismo , Projetos Piloto , Fatores de Risco , Superóxidos/metabolismo
8.
Arq. bras. cardiol ; 91(1): e12-e19, jul. 2008. ilus, tab
Artigo em Inglês, Português | LILACS | ID: lil-486816

RESUMO

A mieloperoxidase (MPO) é uma enzima derivada de leucócitos que catalisa a formação de numerosas espécies reativas oxidantes. Além de integrantes da resposta imune inata, evidências têm comprovado a contribuição desses oxidantes para o dano tecidual durante inflamação. A MPO participa de atividades biológicas pró-aterogênicas relacionadas à evolução da doença cardiovascular, incluindo iniciação, propagação e as fases de complicação aguda do processo aterosclerótico. Dessa forma, a MPO e sua cascata inflamatória representam um alvo atrativo para investigação prognóstica e terapêutica na doença aterosclerótica cardiovascular. Nesta revisão, apresentamos o estado da arte no entendimento das ações biológicas às evidências clínicas da relação entre MPO e doença arterial coronariana. Vários estudos apontam para o efeito independente dos níveis de MPO na evolução da doença e ocorrência de eventos em pacientes com síndrome coronariana aguda. Entretanto, ainda não é consistente o valor preditivo adicional dos níveis de MPO na estratificação de risco cardiovascular para incorporá-la à prática clínica como sinalizadora de vulnerabilidade de placa. Estudos adicionais são necessários para confirmar seu papel nas diferentes formas de apresentação da cardiopatia isquêmica, além da padronização do ensaio, ponto fundamental para a transição desse marcador do ambiente de pesquisa para uso na rotina clínica.


Myeloperoxidase (MPO) is an enzyme derived of leukocytes that catalyze formation of numerous reactive oxidant species. Besides members of the innate host defense, evidences have been proving the contribution of these oxidants to tissue injury during inflammation. MPO participates in proatherogenic biological activities related to the evolution of cardiovascular disease, including initiation, propagation and acute complications of atherosclerotic process. Thereby, MPO and its inflammatory cascade represents an attractive target for prognostical investigation and therapeutics in atherosclerotic cardiovascular disease. In this review, we present the state of the art in the understanding of biological actions to clinical evidences of the relationship between MPO and coronary arterial disease. Several studies point to the independent effect of MPO levels in the evolution of disease and incidence of events in patients with acute coronary syndrome. However, the additional predictive value of MPO levels in the cardiovascular risk assessment, to incorporate it to the clinical practice as marker of plaque vulnerability, is still not consistent. Additional studies are necessary to confirm its role in the different forms of presentation of ischemic disease, besides the standardization of the assay, fundamental point for transition of this marker from research atmosphere to use in clinical routine: : from laboratory to clinical practice.


Assuntos
Humanos , Doenças Cardiovasculares , Peroxidase/fisiologia , Síndrome Coronariana Aguda/diagnóstico , Síndrome Coronariana Aguda/enzimologia , Síndrome Coronariana Aguda/etiologia , Arteriosclerose/diagnóstico , Arteriosclerose/enzimologia , Arteriosclerose/etiologia , Biomarcadores/sangue , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/enzimologia , Doenças Cardiovasculares/etiologia , Doença da Artéria Coronariana/diagnóstico , Doença da Artéria Coronariana/enzimologia , Doença da Artéria Coronariana/etiologia , Metabolismo dos Lipídeos , Óxido Nítrico/metabolismo , Prognóstico , Peroxidase/sangue , Peroxidase/deficiência
9.
Int J Med Sci ; 4(3): 124-30, 2007 Apr 14.
Artigo em Inglês | MEDLINE | ID: mdl-17505560

RESUMO

BACKGROUND: Free radical production is elevated in jugular venous blood emerging from the brain in conjunction with carotid endarterectomy. This study explores the relationships between markers for lesion progression in arteriosclerosis, production of radicals and clinical characteristics. METHODS: The radical production during carotid endarterectomy was studied in 13 patients with an ex vivo spin trap method using OXANOH as a spin trap. MCP-1, ICAM-1, MMP-9 and oxLDL were determined in venous blood samples before, during and after clamping of the carotid artery. Principal component analysis (PCA) as well as partial least square regression analysis (PLS) was applied to interpret the data. RESULTS: PCA and PLS analysis revealed that high values of MMP-9 and low values of ICAM-1 were associated with high radical production whereas MCP-1 and oxLDL were not correlated to radical production. MMP-9 was elevated at diabetes, high haemoglobin, high leucocyte counts and thrombocyte counts as well as at contralateral stenosis, whereas ICAM-1 showed reversed relationships to these clinical variables. MCP-1 increased during surgery. CONCLUSIONS: The main finding in our study is that MMP-9 in plasma is asscociated with radical production during carotid endarterectomy, suggesting that this enzyme might be involved in the pathogenesis of brain damage in conjunction with ischaemia-reperfusion.


Assuntos
Arteriosclerose/sangue , Endarterectomia das Carótidas/efeitos adversos , Radicais Livres/sangue , Metaloproteinase 9 da Matriz/sangue , Idoso , Idoso de 80 Anos ou mais , Arteriosclerose/enzimologia , Arteriosclerose/cirurgia , Biomarcadores/sangue , Quimiocina CCL2/sangue , Feminino , Humanos , Molécula 1 de Adesão Intercelular/sangue , Veias Jugulares , Lipoproteínas LDL/sangue , Masculino , Pessoa de Meia-Idade , Análise de Componente Principal , Análise de Regressão
10.
Arterioscler Thromb Vasc Biol ; 27(2): 394-9, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17110605

RESUMO

OBJECTIVE: A majority of the recognized risk factors for atherosclerosis and the development of cardiovascular disease have been derived from the study of older populations who have already manifested clinical symptoms. If risk factors can be identified earlier in life, such as genetic variation, preventive measures may be taken before overt symptoms of pathology have manifested, and when treatments may be most effective. METHODS AND RESULTS: In an effort to identify individuals at increased risk for cardiovascular disease, we genotyped 732 members of the Muscatine Study Longitudinal Adult Cohort for candidate genetic markers associated with several pathogenetic processes. We identified age-adjusted increased risks for coronary artery calcium (OR 4.29; 95% CI 1.78, 10.31) and increased mean carotid artery intimal-medial thickness associated with the (-444)A>C promoter polymorphism of Leukotriene C4 Synthase (LTC4S) in women. There were no similar associations in men. CONCLUSIONS: LTC4S plays a key role in the process of inflammation as the rate limiting enzyme in the conversion of arachidonic acid to cysteinyl-leukotrienes, important mediators of inflammatory responses. The (-444)C variant upregulates LTC4S mRNA expression, increasing the synthesis of proinflammatory leukotrienes. Our results support genetic variation modifying inflammatory pathways as an important mechanism in the development of atherosclerosis.


Assuntos
Cálcio/metabolismo , Vasos Coronários/enzimologia , Glutationa Transferase/genética , Polimorfismo Genético , Regiões Promotoras Genéticas/genética , Adulto , Fatores Etários , Arteriosclerose/enzimologia , Arteriosclerose/fisiopatologia , Doenças Cardiovasculares , Feminino , Seguimentos , Genótipo , Glutationa Transferase/metabolismo , Humanos , Inflamação , Leucotrienos/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Fatores de Risco , Túnica Íntima/patologia , Regulação para Cima
11.
Exp Biol Med (Maywood) ; 231(6): 794-801, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16741001

RESUMO

Endothelin-converting enzyme (ECE-1) is a critical enzyme in the production of the potent vasoconstrictor peptide endothelin (ET-1). It has previously been shown that the levels of both ET-1 and ECE-1 are raised in atherosclerosis, but the possible relevance of the isoforms of ECE-1 in these changes has not yet been investigated. The aim of this study was to examine the expression of the ECE-1a and ECE-1c isoforms in human atherosclerotic pathologies. Immunohistochemical analysis was carried out on sections from atherosclerotic and non-atherosclerotic vascular tissue using a combination of ECE-1 isoform-specific antibodies, anti-alpha-actin antibodies to identify smooth muscle cells (SMC) and anti-CD68 antibodies to identify macrophages. ECE-1 isoform expression was also examined in cultured SMC and in macrophages isolated from human blood. Results indicated differences in isoform expression in atherosclerotic lesions, with distinct patterns of staining for ECE-1a and ECE-1c. ECE-1c immunoreactivity was seen in macrophages, and also correlated with actin staining. ECE-1a was also localized to macrophages and SMC. Results of this study suggest that these local changes influence the expression patterns of the ECE-1 isoforms within individual cell types. Correlation of these isoform expression patterns with the stage of atherosclerosis could provide novel indicators of disease progression.


Assuntos
Arteriosclerose/enzimologia , Arteriosclerose/patologia , Ácido Aspártico Endopeptidases/metabolismo , Células Espumosas/enzimologia , Metaloendopeptidases/metabolismo , Veia Safena/enzimologia , Aorta/citologia , Ácido Aspártico Endopeptidases/genética , Diferenciação Celular , Células Cultivadas , Enzimas Conversoras de Endotelina , Células Espumosas/citologia , Humanos , Imuno-Histoquímica , Isoenzimas/genética , Isoenzimas/metabolismo , Macrófagos/citologia , Macrófagos/enzimologia , Metaloendopeptidases/genética , Monócitos/citologia , Músculo Liso Vascular/citologia
12.
Ugeskr Laeger ; 168(9): 896-900, 2006 Feb 27.
Artigo em Dinamarquês | MEDLINE | ID: mdl-16513051

RESUMO

5'-adenosine monophosphate-activated protein kinase (AMPK) is an enzyme activated when cellular energy status is threatened. AMPK activates energy-providing processes, while energy-consuming processes are inhibited. AMPK is also involved in regulation of gene expression and in appetite control. Pharmacological activation of AMPK in animal models of the metabolic syndrome leads to marked amelioration of symptoms. Some antidiabetic drugs activate AMPK, and activation also occurs during physical exercise. It is likely that part of the effect of physical activity in preventing the development of diseases related to a sedentary lifestyle is due to activation of AMPK.


Assuntos
Doenças Metabólicas/enzimologia , Síndrome Metabólica/enzimologia , Complexos Multienzimáticos/metabolismo , Proteínas Quinases/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo , Proteínas Quinases Ativadas por AMP , Animais , Arteriosclerose/enzimologia , Metabolismo Energético , Ativação Enzimática , Regulação Enzimológica da Expressão Gênica , Humanos , Resistência à Insulina , Estilo de Vida , Complexos Multienzimáticos/genética , Músculo Esquelético/enzimologia , Proteínas Quinases/genética , Proteínas Serina-Treonina Quinases/genética
13.
Nucleic Acids Res ; 33(16): 5308-19, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16177180

RESUMO

Activation of the transcription factor NF-kappaB is critical for the tumor necrosis factor-alpha (TNF-alpha)-induced inflammatory response. Here we report the complete gene expression profile from activated microvascular endothelial cells emphasizing the direct contribution of the NF-kappaB pathway. Human microvascular endothelial cell line-1 (HMEC-1) cells were modified to express dominant interfering mutants of the IKK/NF-kappaB signaling module and expression profiles were determined. Our results provide compelling evidence for the virtually absolute dependence of TNF-alpha-regulated genes on NF-kappaB. A constitutively active IKK2 was sufficient for maximal induction of most target genes, whereas a transdominant IkappaBalpha suppressed gene expression. Several genes with a critical role in atherogenesis were identified. The endothelial lipase (EL) gene, a key enzyme involved in lipoprotein metabolism, was investigated more in detail. Binding sites interacting with NF-kappaB in vitro and in vivo were identified and co-transfection experiments demonstrated the direct regulation of the EL promoter by NF-kappaB. We conclude that targeting the IKK/NF-kappaB pathway or specific genes downstream may be effective for the control or prevention of chronic inflammatory diseases such as atherosclerosis.


Assuntos
Endotélio Vascular/metabolismo , Lipase/genética , NF-kappa B/fisiologia , Fator de Necrose Tumoral alfa/farmacologia , Arteriosclerose/enzimologia , Arteriosclerose/genética , Linhagem Celular , Células Cultivadas , Proteínas do Citoesqueleto/metabolismo , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Endotélio Vascular/citologia , Endotélio Vascular/enzimologia , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Humanos , Quinase I-kappa B , Mediadores da Inflamação/farmacologia , Mutação , NF-kappa B/antagonistas & inibidores , NF-kappa B/metabolismo , Plaquinas , Regiões Promotoras Genéticas , Proteínas Serina-Treonina Quinases/genética , Proteínas Serina-Treonina Quinases/metabolismo , Transdução de Sinais , Fator de Transcrição RelA
14.
Biochim Biophys Acta ; 1736(1): 30-7, 2005 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-16081317

RESUMO

Leukotrienes (LTs) are powerful inflammatory lipid mediators derived from the 5-lipoxygenase (5-LO) cascade of arachidonic acid. Recent clinical, population genetic, cell biological, and mouse studies indicate participation of the 5-LO pathway in atherogenesis and arterial wall remodeling. 5-LO is expressed by leukocytes including blood monocytes, tissue macrophages, dendritic cells, neutrophils, and mast cells. LTB4 and the cysteinyl LTs LTC4, LTD4, and LTE4, act through two BLT and two cysLT receptors that are differentially expressed on hematopoietic and arterial wall cells. The precise roles of LTs or the LT receptors in cardiovascular physiology remain largely to be explored. In this review, we will discuss what is currently known about the 5-LO atherosclerosis connection. We will attempt to propose strategies to further explore potential links between the 5-LO pathway and blood vessel physiology and disease progression.


Assuntos
Araquidonato 5-Lipoxigenase/fisiologia , Artérias/enzimologia , Arteriosclerose/enzimologia , Transdução de Sinais/fisiologia , Animais , Arteriosclerose/genética , Camundongos , Transdução de Sinais/genética
15.
Biol Pharm Bull ; 28(7): 1239-43, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15997106

RESUMO

Chronic inhibition of nitric oxide (NO) synthesis by administration of high dose of N(G)-nitro-L-arginine methylester (L-NAME) induces vascular inflammation and subsequent atherosclerosis. We aimed to investigate whether the methanol extract of Sorbus commixta cortex (MSC) is able to prevent inflammatory process in a rat model of L-NAME-induced atherosclerosis. Chronic treatment with low or high doses of MSC prevented the L-NAME-induced increase in monocyte chemoattractant protein-1 (MCP-1) and nuclear factor-kappaB (NF-kappaB) p65 expressions as well as adhesion molecules including intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), and E-selectin in aorta. In addition, increased endothelin-1 (ET-1) and angiotensin converting enzyme (ACE) expressions and decreased endothelial cell NO synthase (ecNOS) expression in aorta from L-NAME treated group was reversed by treatment with MSC. From the histological examination, aortic segment from the L-NAME-treated rats revealed a thickening of intima and media, which was ameliorated by treatment with MSC. In conclusion, our results indicate that MSC can prevent atherosclerosis by inhibiting vascular over-expressions of vasoactive materials, pro-inflammatory transcription factor, and adhesion molecules and by augmenting ecNOS in chronic L-NAME-treated rat model.


Assuntos
Arteriosclerose/induzido quimicamente , Metanol/química , NG-Nitroarginina Metil Éster/toxicidade , Extratos Vegetais/farmacologia , Sorbus/química , Animais , Arteriosclerose/enzimologia , Arteriosclerose/metabolismo , Sequência de Bases , Moléculas de Adesão Celular/metabolismo , Quimiocina CCL2/metabolismo , Primers do DNA , Endotelina-1/genética , NF-kappa B/metabolismo , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo III , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fator de Transcrição RelA
16.
J Mol Cell Cardiol ; 39(3): 443-52, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16040051

RESUMO

Cyclooxygenase (COX) 2 is expressed in atherosclerotic lesions. We have previously reported that selective inhibition of COX-2 reduces early atherosclerosis in LDLR deficient mice. To examine the role of COX-2 in atherosclerosis in other mouse models, we studied the effects of selective COX-2 inhibition (by rofecoxib and NS-398) and nonselective COX inhibition (by indomethacin) on early atherosclerotic lesion formation in apolipoprotein E-deficient (apoE(-/-)) mice. Selective COX-2 and nonselective COX inhibition reduced atherosclerosis in female apoE(-/-) mice by 35-38% and 38-51% in the proximal and en face aortas, respectively. Next we investigated the role of macrophage COX-2 by transplanting COX-2(-/-) fetal liver cells into C57BL/6 mice and challenging the mice with an atherogenic diet. Genetic deletion of COX-2 from hematopoietic cells reduced atherosclerosis by 51%. In addition, LPS activated COX-2(-/-) macrophages had decreased expression of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNFalpha). The results demonstrate that selective inhibition of COX-2 and elimination of COX-2 from macrophages significantly reduces early atherosclerotic lesion formation in apoE-deficient and C57BL/6 mice. These results are compatible with COX-2 expression by macrophages having a proatherogenic role, and support the potential of anti-inflammatory therapeutic approaches for atherosclerosis.


Assuntos
Apolipoproteínas E/deficiência , Arteriosclerose/etiologia , Arteriosclerose/patologia , Prostaglandina-Endoperóxido Sintases/metabolismo , Animais , Aorta/metabolismo , Aorta/patologia , Apolipoproteínas E/genética , Arteriosclerose/enzimologia , Arteriosclerose/genética , Células Cultivadas , Quimiocina CCL2/metabolismo , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/farmacologia , Feminino , Imuno-Histoquímica , Indometacina/farmacologia , Lactonas/farmacologia , Lipopolissacarídeos/farmacologia , Transplante de Fígado , Macrófagos/enzimologia , Macrófagos/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Nitrobenzenos/farmacologia , Sulfonamidas/farmacologia , Sulfonas/farmacologia , Transplante Heterólogo , Fator de Necrose Tumoral alfa/metabolismo
17.
Proc Natl Acad Sci U S A ; 102(31): 11029-34, 2005 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-16043712

RESUMO

Resident macrophages (i.e., Kupffer cells) are derived from hematopoietic stem cells (HSCs) and are primarily responsible for the removal from plasma of oxidized forms of low-density lipoprotein (LDL). The therapeutic potential of Kupffer cell expression of a transgene encoding paraoxonase-1 (PON1), whose plasma activity correlates with the protection from atherosclerosis, was examined in mice rendered atherosclerosis-susceptible through genetic deletion of the LDL receptor. Mice having their bone marrow engrafted with HSCs expressing the PON1 transgene (PON1-Tg) driven by a macrophage-specific promoter were injected i.v. with saline (vehicle only) or with gadolinium chloride (GdCl(3)), an agent that rapidly causes Kupffer cell apoptosis. One month later, GdCl(3)-facilitated Kupffer cell apoptosis increased the hepatic expression of transgenic PON1 mRNA by 9-fold. After 12 weeks of being fed a cholesterol-enriched atherogenic diet, mice injected with GdCl(3) exhibited 50% reductions in both aortic sinus atherosclerotic lesions (P < 0.0097) and surface lesions of the abdominal aorta (P < 0.006). In contrast, mice receiving HSCs expressing the PON1-Tg but not treated with GdCl(3) showed no protection from atherosclerosis. In addition, mice engrafted with HSCs not expressing the PON1-Tg but injected with GdCl(3) also showed no protection from atherosclerosis. These findings, showing that GdCl(3)-enhanced hepatic expression of the PON1-Tg is essential for reducing atherosclerosis, indicate that Kupffer cells play an important role in atherogenesis. GdCl(3)-facilated replacement of Kupffer cells may enhance the efficacy of other HSC-based gene therapies.


Assuntos
Arteriosclerose/terapia , Arildialquilfosfatase/genética , Gadolínio/farmacologia , Células de Kupffer/efeitos dos fármacos , Células de Kupffer/enzimologia , Animais , Arteriosclerose/enzimologia , Arteriosclerose/genética , Arteriosclerose/patologia , Sequência de Bases , Transplante de Medula Óssea , DNA Complementar/genética , Expressão Gênica , Terapia Genética , Células de Kupffer/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Transgênicos , Receptores de LDL/deficiência , Receptores de LDL/genética
18.
Metab Brain Dis ; 20(2): 97-103, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15938128

RESUMO

In the present study we investigate the effect of homocysteine (Hcy) administration, the main metabolite accumulating in homocystinuria, on butyrylcholinesterase (BuChE) activity in serum of rats. For the acute treatment, 29-day-old Wistar rats received one subcutaneous injection of Hcy (0.6 micromol/g) or saline (control) and were killed 1 h later. For the chronic treatment, Hcy was administered subcutaneously to rats from the 6th to the 28th day of life. Control rats received saline. The rats were killed 12 h after the last injection. In another set of experiments, rats were pretreated for one week with vitamins E and C or saline and 12 h after the last injection received one single injection of Hcy or saline, being killed 1 h later. Serum was used to determine BuChE activity. Our results showed that acute and chronic administration of Hcy significantly decreased BuChE activity. Furthermore, vitamins E and C per se did not alter BuChE activity, but prevented the reduction of this enzyme activity caused by acute administration of Hcy. The data suggest that the inhibitory effect of Hcy on BuChE activity is probably mediated by free radicals, since vitamins E and C administration prevented such effect.


Assuntos
Butirilcolinesterase/sangue , Regulação para Baixo/efeitos dos fármacos , Homocistinúria/enzimologia , Hiper-Homocisteinemia/enzimologia , Animais , Antioxidantes/metabolismo , Antioxidantes/farmacologia , Arteriosclerose/enzimologia , Arteriosclerose/fisiopatologia , Ácido Ascórbico/metabolismo , Ácido Ascórbico/farmacologia , Modelos Animais de Doenças , Regulação para Baixo/fisiologia , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/fisiologia , Radicais Livres/antagonistas & inibidores , Radicais Livres/metabolismo , Homocisteína/metabolismo , Homocisteína/farmacologia , Homocistinúria/sangue , Homocistinúria/tratamento farmacológico , Hiper-Homocisteinemia/sangue , Hiper-Homocisteinemia/tratamento farmacológico , Metabolismo dos Lipídeos , Estresse Oxidativo/efeitos dos fármacos , Estresse Oxidativo/fisiologia , Ratos , Ratos Wistar , Vitamina E/metabolismo , Vitamina E/farmacologia
19.
J Recept Signal Transduct Res ; 25(1): 19-33, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15960392

RESUMO

The present study examined the cellular functions of low-molecular-weight protein tyrosine phosphatase (LMW-PTP), which consists of two active isoforms IF-1 and IF-2, in vascular smooth muscle cells (VSMCs) and endothelial cells (ECs), focusing on cell growth and migration. We transduced recombinant IF-1 and IF-2, and ribozyme targeting both isoforms using an adenovirus vector in these cells. We detected the expression of IF-1 and IF-2 in both types of cells. IF-1 as well as IF-2 inhibited PDGF-induced DNA synthesis and migration in VSMCs. In contrast, both isoforms enhanced lysophosphatidic acid-stimulated cell migration without change in DNA synthesis in ECs. Whereas there is a report indicating that reactive oxygen species-dependent inactivation of LMW-PTP regulates actin cytoskeleton reorganization during cell spreading and migration, the isoforms conversely suppressed the PDGF-induced H2O2 generation with subsequent decrease in the p38 activity in VSMCs. Catalytically inactive LMW-PTP exerted the opposite and similar effects to the wild type in ECs and in VSMCs, respectively, suggesting that substrates for the phosphatase differ between these cells. Moreover, high concentrations of glucose suppressed the expression of LMW-PTP in both cells. These data suggest that LMW-PTP negatively regulates the pathogenesis of atherosclerosis and that glucose-dependent suppression of LMW-PTP expression may promote the development of atherosclerosis in diabetics.


Assuntos
Endotélio Vascular/enzimologia , Músculo Liso Vascular/enzimologia , Proteínas Tirosina Fosfatases/metabolismo , Animais , Arteriosclerose/enzimologia , Arteriosclerose/etiologia , Células Cultivadas , DNA/biossíntese , DNA Complementar/genética , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Glucose/farmacologia , Isoenzimas/química , Isoenzimas/genética , Isoenzimas/metabolismo , Peso Molecular , Músculo Liso Vascular/citologia , Músculo Liso Vascular/efeitos dos fármacos , Fator de Crescimento Derivado de Plaquetas/farmacologia , Proteínas Tirosina Fosfatases/química , Proteínas Tirosina Fosfatases/genética , Ratos , Transdução de Sinais/efeitos dos fármacos , Suínos
20.
Circulation ; 111(21): 2820-7, 2005 May 31.
Artigo em Inglês | MEDLINE | ID: mdl-15911696

RESUMO

BACKGROUND: Accumulation of macrophages and their in situ expression of matrix metalloproteinases (MMPs) are important determinants of plaque stability. Activation of membrane-bound MT1-MMP, the major activator of pro-MMP-2, requires intracellular endoproteolytic cleavage of its precursor protein. This type of activation typically requires suitable furin-like proprotein convertases (PCs), specifically furin and PC5. The present study was done to investigate the function of MT1-MMP as well as furin-like PCs in mononuclear inflammatory cells. METHODS AND RESULTS: Macrophage differentiation of human monocytic THP-1 cells was accompanied by increased expression of furin, PC5, and MT1-MMP. Some pro-MMP-2 activation was found in macrophages, but pro-MMP-2 level or activation was not enhanced after stimulation with the proinflammatory mediators tumor necrosis factor-alpha or lipopolysaccharide. However, culturing of macrophages in conditioned medium from serum-starved vascular smooth muscle cells, which constitutively secrete pro-MMP-2, resulted in a strong pro-MMP-2 activation. Inhibition of furin-like PCs with the specific pharmacological inhibitor decanoyl-RVKR-chloromethylketone (dec-CMK) inhibited MT1-MMP activation in macrophages. Dec-CMK or furin-specific small interfering RNA significantly inhibited macrophage MT1-MMP-dependent activation of vascular smooth muscle cell-derived pro-MMP-2. Flow cytometry demonstrated that human circulating monocytes express furin and PC5, and MT1-MMP and immunohistochemistry revealed their colocalization in macrophages in advanced human atherosclerotic lesions. CONCLUSIONS: Furin-like PCs (furin and PC5) play a central role in a MT-MMP-MMP-2 proteolytic cascade, involving provision of macrophage MT1-MMP for the activation of pro-MMP-2 synthesized by other cells. Furin and PC5 are expressed in human peripheral blood mononuclear cells and colocalize with MT1-MMP in macrophages in the atherosclerotic plaque, supporting the hypothesis that they are potential targets in atherosclerosis.


Assuntos
Arteriosclerose/enzimologia , Metaloproteinase 2 da Matriz/metabolismo , Pró-Proteína Convertases/fisiologia , Arteriosclerose/etiologia , Células Cultivadas , Meios de Cultivo Condicionados/farmacologia , Furina/análise , Furina/fisiologia , Humanos , Macrófagos/citologia , Macrófagos/enzimologia , Metaloproteinases da Matriz/metabolismo , Metaloproteinases da Matriz Associadas à Membrana , Miócitos de Músculo Liso/citologia , Miócitos de Músculo Liso/metabolismo , Pró-Proteína Convertase 5/análise , Pró-Proteína Convertase 5/fisiologia , Pró-Proteína Convertases/análise , Precursores de Proteínas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA